Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase
- PMID: 37128776
- DOI: 10.1002/ajh.26943
Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase
References
REFERENCES
-
- Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984.
-
- Ohanian M, Kantarjian HM, Shoukier M, et al. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020;95:1127-1134.
-
- Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288-1294.
-
- Mnatzaganian G, Davidson DC, Hiller JE, Ryan P. Propensity score matching and randomization. J Clin Epidemiol. 2015;68(7):760-768.
-
- Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, eds. Institute of Medicine Committee on standards for developing trustworthy clinical practice G. Clinical Practice Guidelines We Can Trust. National Academies Press (US); 2011.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical